Search

Your search keyword '"Mulligan, Mark J."' showing total 469 results
Start Over Author "Mulligan, Mark J." Language english
469 results on '"Mulligan, Mark J."'

2. Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials

Author

Happe, Myra, Hofstetter, Amelia R., Wang, Jing, Yamshchikov, Galina V., Holman, LaSonji A., Novik, Laura, Strom, Larisa, Kiweewa, Francis, Wakabi, Salim, Millard, Monica, Kelley, Colleen F., Kabbani, Sarah, Edupuganti, Srilatha, Beck, Allison, Kaltovich, Florence, Murray, Tamar, Tsukerman, Susanna, Carr, Derick, Ashman, Carl, Stanley, Daphne A., Ploquin, Aurélie, Bailer, Robert T., Schwartz, Richard, Cham, Fatim, Tindikahwa, Allan, Hu, Zonghui, Gordon, Ingelise J., Rouphael, Nadine, Houser, Katherine V., Coates, Emily E., Graham, Barney S., Koup, Richard A., Mascola, John R., Sullivan, Nancy J., Robb, Merlin L., Ake, Julie A., Lyke, Kirsten E., Mulligan, Mark J., Ledgerwood, Julie E., and Kibuuka, Hannah

Published
2024
Full Text
View/download PDF

3. Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

Author

Axfors, Cathrine, Schmitt, Andreas M., Janiaud, Perrine, van’t Hooft, Janneke, Abd-Elsalam, Sherief, Abdo, Ehab F., Abella, Benjamin S., Akram, Javed, Amaravadi, Ravi K., Angus, Derek C., Arabi, Yaseen M., Azhar, Shehnoor, Baden, Lindsey R., Baker, Arthur W., Belkhir, Leila, Benfield, Thomas, Berrevoets, Marvin A. H., Chen, Cheng-Pin, Chen, Tsung-Chia, Cheng, Shu-Hsing, Cheng, Chien-Yu, Chung, Wei-Sheng, Cohen, Yehuda Z., Cowan, Lisa N., Dalgard, Olav, de Almeida e Val, Fernando F., de Lacerda, Marcus V. G., de Melo, Gisely C., Derde, Lennie, Dubee, Vincent, Elfakir, Anissa, Gordon, Anthony C., Hernandez-Cardenas, Carmen M., Hills, Thomas, Hoepelman, Andy I. M., Huang, Yi-Wen, Igau, Bruno, Jin, Ronghua, Jurado-Camacho, Felipe, Khan, Khalid S., Kremsner, Peter G., Kreuels, Benno, Kuo, Cheng-Yu, Le, Thuy, Lin, Yi-Chun, Lin, Wu-Pu, Lin, Tse-Hung, Lyngbakken, Magnus Nakrem, McArthur, Colin, McVerry, Bryan J., Meza-Meneses, Patricia, Monteiro, Wuelton M., Morpeth, Susan C., Mourad, Ahmad, Mulligan, Mark J., Murthy, Srinivas, Naggie, Susanna, Narayanasamy, Shanti, Nichol, Alistair, Novack, Lewis A., O’Brien, Sean M., Okeke, Nwora Lance, Perez, Léna, Perez-Padilla, Rogelio, Perrin, Laurent, Remigio-Luna, Arantxa, Rivera-Martinez, Norma E., Rockhold, Frank W., Rodriguez-Llamazares, Sebastian, Rolfe, Robert, Rosa, Rossana, Røsjø, Helge, Sampaio, Vanderson S., Seto, Todd B., Shahzad, Muhammad, Soliman, Shaimaa, Stout, Jason E., Thirion-Romero, Ireri, Troxel, Andrea B., Tseng, Ting-Yu, Turner, Nicholas A., Ulrich, Robert J., Walsh, Stephen R., Webb, Steve A., Weehuizen, Jesper M., Velinova, Maria, Wong, Hon-Lai, Wrenn, Rebekah, Zampieri, Fernando G., Zhong, Wu, Moher, David, Goodman, Steven N., Ioannidis, John P. A., and Hemkens, Lars G.

Published
2024
Full Text
View/download PDF

4. Enhanced D614G and Omicron Variants Antibody Persistence in Infants at 2 Months of Age Following Maternal mRNA Booster Vaccination During Pregnancy or Postpartum

Author

Munoz, Flor M., Beigi, Richard, Posavad, Christine M., Kelly, Clifton, Badell, Martina L., Bunge, Katherine, Mulligan, Mark J., Parameswaran, Lalitha, Richardson, Barbra A., Olsen-Chen, Courtney, Novak, Richard M., Brady, Rebecca C., DeFranco, Emily, Gerber, Jeffrey S., Shriver, Mallory, Suthar, Mehul S., Coler, Rhea, Berube, Bryan J., Kim, So Hee, Piper, Jeanna M., Miedema, Joy, Pasetti, Marcela, Neuzil, Kathleen M., and Cardemil, Cristina V.

Published
2024
Full Text
View/download PDF

5. Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adults

Author

Phadke, Varun K., Gromer, Daniel J., Rebolledo, Paulina A., Graciaa, Daniel S., Wiley, Zanthia, Sherman, Amy C., Scherer, Erin M., Leary, Maranda, Girmay, Tigisty, McCullough, Michele P., Min, Ji-Young, Capone, Stefania, Sommella, Andrea, Vitelli, Alessandra, Retallick, Jamie, Seetahal, Janine, Koller, Mark, Tsong, Rachel, Neill-Gubitz, Hannah, Mulligan, Mark J., and Rouphael, Nadine G.

Published
2024
Full Text
View/download PDF

6. Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial

Author

Davey, Richard T, Jr., Collins, Gary L, Rouphael, Nadine, Poliquin, Guillaume, McConnell, Rosemary, Grubbs, Gabrielle, Moir, Susan L, Langley, Joanne M, Teitelbaum, Marc, Hewlett, Angela L, McLellan, Susan L F, Bhadelia, Nahid, Raabe, Vanessa N, Mulligan, Mark J, Maljkovic Berry, Irina, Dighero-Kemp, Bonnie, Kurtz, Jonathan R, Hensley, Lisa E, Dozier, Nelson C E, Marron, Lindsay C B, DuChene, Alain, Kuhn, Jens H, Brown, Shawn K, Khurana, Surender, Lane, H Clifford, and Neaton, James D

Published
2024
Full Text
View/download PDF

9. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

Author

Branche, Angela R., Rouphael, Nadine G., Diemert, David J., Falsey, Ann R., Losada, Cecilia, Baden, Lindsey R., Frey, Sharon E., Whitaker, Jennifer A., Little, Susan J., Anderson, Evan J., Walter, Emmanuel B., Novak, Richard M., Rupp, Richard, Jackson, Lisa A., Babu, Tara M., Kottkamp, Angelica C., Luetkemeyer, Anne F., Immergluck, Lilly C., Presti, Rachel M., Bäcker, Martín, Winokur, Patricia L., Mahgoub, Siham M., Goepfert, Paul A., Fusco, Dahlene N., Malkin, Elissa, Bethony, Jeffrey M., Walsh, Edward E., Graciaa, Daniel S., Samaha, Hady, Sherman, Amy C., Walsh, Stephen R., Abate, Getahun, Oikonomopoulou, Zacharoula, El Sahly, Hana M., Martin, Thomas C. S., Kamidani, Satoshi, Smith, Michael J., Ladner, Benjamin G., Porterfield, Laura, Dunstan, Maya, Wald, Anna, Davis, Tamia, Atmar, Robert L., Mulligan, Mark J., Lyke, Kirsten E., Posavad, Christine M., Meagher, Megan A., Stephens, David S., Neuzil, Kathleen M., Abebe, Kuleni, Hill, Heather, Albert, Jim, Telu, Kalyani, Mu, Jinjian, Lewis, Teri C., Giebeig, Lisa A., Eaton, Amanda, Netzl, Antonia, Wilks, Samuel H., Türeli, Sina, Makhene, Mamodikoe, Crandon, Sonja, Montefiori, David C., Makowski, Mat, Smith, Derek J., Nayak, Seema U., Roberts, Paul C., and Beigel, John H.

Published
2023
Full Text
View/download PDF

10. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants

Author

Lyke, Kirsten E., Atmar, Robert L., Dominguez Islas, Clara, Posavad, Christine M., Deming, Meagan E., Branche, Angela R., Johnston, Christine, El Sahly, Hana M., Edupuganti, Srilatha, Mulligan, Mark J., Jackson, Lisa A., Rupp, Richard E., Rostad, Christina A., Coler, Rhea N., Bäcker, Martín, Kottkamp, Angelica C., Babu, Tara M., Dobrzynski, David, Martin, Judith M., Brady, Rebecca C., Frenck, Jr., Robert W., Rajakumar, Kumaravel, Kotloff, Karen, Rouphael, Nadine, Szydlo, Daniel, PaulChoudhury, Rahul, Archer, Janet I., Crandon, Sonja, Ingersoll, Brian, Eaton, Amanda, Brown, Elizabeth R., McElrath, M. Juliana, Neuzil, Kathleen M., Stephens, David S., Post, Diane J., Lin, Bob C., Serebryannyy, Leonid, Beigel, John H., Montefiori, David C., and Roberts, Paul C.

Published
2023
Full Text
View/download PDF

11. mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection

Author

Ivanova, Ellie N., Shwetar, Jasmine, Devlin, Joseph C., Buus, Terkild B., Gray-Gaillard, Sophie, Koide, Akiko, Cornelius, Amber, Samanovic, Marie I., Herrera, Alberto, Mimitou, Eleni P., Zhang, Chenzhen, Karmacharya, Trishala, Desvignes, Ludovic, Ødum, Niels, Smibert, Peter, Ulrich, Robert J., Mulligan, Mark J., Koide, Shohei, Ruggles, Kelly V., Herati, Ramin S., and Koralov, Sergei B.

Published
2023
Full Text
View/download PDF

12. Natural infection by Zika virus but not DNA vaccination consistently elicits antibodies that compete with two potently neutralising monoclonal antibodies targeting distinct epitopes

Author

Smith, Teresa C., Espinoza, Daniel O., Zhu, Yerun, Cardona-Ospina, Jaime A., Bowman, Natalie M., Becker-Dreps, Sylvia, Rouphael, Nadine, Rodriguez-Morales, Alfonso J., Bucardo, Filemon, Edupuganti, Srilatha, Premkumar, Lakshmanane, Mulligan, Mark J., de Silva, Aravinda M., and Collins, Matthew H.

Published
2023
Full Text
View/download PDF

17. Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans

Author

Ellebedy, Ali H., Nachbagauer, Raffael, Jackson, Katherine J. L., Dai, Ya-Nan, Han, Julianna, Alsoussi, Wafaa B., Davis, Carl W., Stadlbauer, Daniel, Rouphael, Nadine, Chromikova, Veronika, McCausland, Megan, Chang, Cathy Y., Cortese, Mario, Bower, Mary, Chennareddy, Chakravarthy, Schmitz, Aaron J., Zarnitsyna, Veronika I., Lai, Lilin, Rajabhathor, Arvind, Kazemian, Cheyann, Antia, Rustom, Mulligan, Mark J., Ward, Andrew B., Fremont, Daved H., Boyd, Scott D., Pulendran, Bali, Krammer, Florian, and Ahmed, Rafi

Published
2020

19. The New York State SARS-CoV-2 Testing Consortium: Regional Communication in Response to the COVID-19 Pandemic

Author

Crawford, James M., Aguero-Rosenfeld, Maria E., Aifantis, Ioannis, Cadoff, Evan M., Cangiarella, Joan F., Cordon-Cardo, Carlos, Cushing, Melissa, Firpo-Betancourt, Aldolfo, Fox, Amy S., Furuya, Yoko, Hacking, Sean, Jhang, Jeffrey, Leonard, Debra G.B., Libien, Jenny, Loda, Massimo, Mendu, Damadora Rao, Mulligan, Mark J., Nasr, Michel R., Pecora, Nicole D., Pessin, Melissa S., Prystowsky, Michael B., Ramanathan, Lakshmi V., Rauch, Kathleen R., Riddell, Scott, Roach, Karen, Roth, Kevin A., Shroyer, Kenneth R., Smoller, Bruce R., Spitalnik, Steven L., Spitzer, Eric D., Tomaszewski, John E., Waltman, Susan, Willis, Loretta, and Sumer-King, Zeynep

Published
2021
Full Text
View/download PDF

21. Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination.

Author

Kister, Ilya, Curtin, Ryan, Piquet, Amanda L., Borko, Tyler, Pei, Jinglan, Banbury, Barbara L, Bacon, Tamar E., Kim, Angie, Tuen, Michael, Velmurugu, Yogambigai, Nyovanie, Samantha, Selva, Sean, Samanovic, Marie I., Mulligan, Mark J., Patskovsky, Yury, Priest, Jessica, Cabatingan, Mark, Winger, Ryan C., Krogsgaard, Michelle, and Silverman, Gregg J.

Subjects
COVID-19 vaccines, BOOSTER vaccines, SARS-CoV-2, IMMUNITY, COVID-19
Abstract

Objectives: (1) To plot the trajectory of humoral and cellular immune responses to the primary (two‐dose) COVID‐19 mRNA series and the third/booster dose in B‐cell‐depleted multiple sclerosis (MS) patients up to 2 years post‐vaccination; (2) to identify predictors of immune responses to vaccination; and (3) to assess the impact of intercurrent COVID‐19 infections on SARS CoV‐2‐specific immunity. Methods: Sixty ocrelizumab‐treated MS patients were enrolled from NYU (New York) and University of Colorado (Anschutz) MS Centers. Samples were collected pre‐vaccination, and then 4, 12, 24, and 48 weeks post‐primary series, and 4, 12, 24, and 48 weeks post‐booster. Binding anti‐Spike antibody responses were assessed with multiplex bead‐based immunoassay (MBI) and electrochemiluminescence (Elecsys®, Roche Diagnostics), and neutralizing antibody responses with live‐virus immunofluorescence‐based microneutralization assay. Spike‐specific cellular responses were assessed with IFNγ/IL‐2 ELISpot (Invitrogen) and, in a subset, by sequencing complementarity determining regions (CDR)‐3 within T‐cell receptors (Adaptive Biotechnologies). A linear mixed‐effect model was used to compare antibody and cytokine levels across time points. Multivariate analyses identified predictors of immune responses. Results: The primary vaccination induced an 11‐ to 208‐fold increase in binding and neutralizing antibody levels and a 3‐ to 4‐fold increase in IFNγ/IL‐2 responses, followed by a modest decline in antibody but not cytokine responses. Booster dose induced a further 3‐ to 5‐fold increase in binding antibodies and 4‐ to 5‐fold increase in IFNγ/IL‐2, which were maintained for up to 1 year. Infections had a variable impact on immunity. Interpretation: Humoral and cellular benefits of COVID‐19 vaccination in B‐cell‐depleted MS patients were sustained for up to 2 years when booster doses were administered. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Author

Mulligan, Mark J., Lyke, Kirsten E., Kitchin, Nicholas, Absalon, Judith, Gurtman, Alejandra, Lockhart, Stephen, and Neuzil, Kathleen

Subjects
Clinical trials -- Forecasts and trends, Market trend/market analysis, Environmental issues, Science and technology, Zoology and wildlife conservation, Comirnaty (Vaccine) -- Dosage and administration -- Testing
Abstract

In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).sup.1, a pandemic. With rapidly accumulating numbers of cases and deaths reported globally.sup.2, a vaccine is urgently needed. Here we report the available safety, tolerability and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose-escalation study (ClinicalTrials.gov identifier NCT04368728) among 45 healthy adults (18-55 years of age), who were randomized to receive 2 doses--separated by 21 days--of 10 [mu]g, 30 [mu]g or 100 [mu]g of BNT162b1. BNT162b1 is a lipid-nanoparticle-formulated, nucleoside-modified mRNA vaccine that encodes the trimerized receptor-binding domain (RBD) of the spike glycoprotein of SARS-CoV-2. Local reactions and systemic events were dose-dependent, generally mild to moderate, and transient. A second vaccination with 100 [mu]g was not administered because of the increased reactogenicity and a lack of meaningfully increased immunogenicity after a single dose compared with the 30-[mu]g dose. RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second dose. Geometric mean neutralizing titres reached 1.9-4.6-fold that of a panel of COVID-19 convalescent human sera, which were obtained at least 14 days after a positive SARS-CoV-2 PCR. These results support further evaluation of this mRNA vaccine candidate. In a dose-escalation study of the COVID-19 RNA vaccine BNT162b1 in 45 healthy adults, RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second vaccine dose., Author(s): Mark J. Mulligan [sup.1] [sup.2] , Kirsten E. Lyke [sup.3] , Nicholas Kitchin [sup.4] , Judith Absalon [sup.5] , Alejandra Gurtman [sup.5] , Stephen Lockhart [sup.4] , Kathleen Neuzil [...]

Published
2020
Full Text
View/download PDF

25. Theory-Based Analysis of Interest in an HIV Vaccine for Reasons Indicative of Risk Compensation among African American Women

Author

Painter, Julia E., Temple, Brandie S., Woods, Laura A., Cwiak, Carrie, Haddad, Lisa B., Mulligan, Mark J., and DiClemente, Ralph J.

Abstract

Licensure of an HIV vaccine could reduce or eliminate HIV among vulnerable populations. However, vaccine effectiveness could be undermined by risk compensation (RC), defined by an increase in risky behavior due to a belief that the vaccine will confer protection. Interest in an HIV vaccine for reasons indicative of RC may serve as an indicator of actual RC in a postlicensure era. This study assessed factors associated with interest in an HIV vaccine for reasons indicative of RC among African American women aged 18 to 55 years, recruited from a hospital-based family planning clinic in Atlanta, Georgia (N = 321). Data were collected using audio-computer-assisted surveys. Survey items were guided by risk homeostasis theory and social cognitive theory. Multivariable logistic regression was used to assess determinants of interest in an HIV vaccine for reasons indicative of RC. Thirty-eight percent of the sample expressed interest in an HIV vaccine for at least one reason indicative of RC. In the final model, interest in an HIV vaccine for reasons indicative of RC was positively associated with higher impulsivity, perceived benefits of sexual risk behaviors, and perceived benefits of HIV vaccination; it was negatively associated with having at least some college education, positive future orientation, and self-efficacy for sex refusal. Results suggest that demographic, personality, and theory-based psychosocial factors are salient to wanting an HIV vaccine for reasons indicative of RC, and underscore the need for risk-reduction counseling alongside vaccination during the eventual rollout of an HIV vaccine.

Published
2018
Full Text
View/download PDF

26. Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities

Author

Noval, Maria G., Kaczmarek, Maria E., Koide, Akiko, Rodriguez-Rodriguez, Bruno A., Louie, Ping, Tada, Takuya, Hattori, Takamitsu, Panchenko, Tatyana, Romero, Larizbeth A., Teng, Kai Wen, Bazley, Andrew, de Vries, Maren, Samanovic, Marie I., Weiser, Jeffrey N., Aifantis, Ioannis, Cangiarella, Joan, Mulligan, Mark J., Desvignes, Ludovic, Dittmann, Meike, Landau, Nathaniel R., Aguero-Rosenfeld, Maria, Koide, Shohei, and Stapleford, Kenneth A.

Published
2021
Full Text
View/download PDF

27. Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

Author

Axfors, Cathrine, Schmitt, Andreas M., Janiaud, Perrine, van’t Hooft, Janneke, Abd-Elsalam, Sherief, Abdo, Ehab F., Abella, Benjamin S., Akram, Javed, Amaravadi, Ravi K., Angus, Derek C., Arabi, Yaseen M., Azhar, Shehnoor, Baden, Lindsey R., Baker, Arthur W., Belkhir, Leila, Benfield, Thomas, Berrevoets, Marvin A. H., Chen, Cheng-Pin, Chen, Tsung-Chia, Cheng, Shu-Hsing, Cheng, Chien-Yu, Chung, Wei-Sheng, Cohen, Yehuda Z., Cowan, Lisa N., Dalgard, Olav, de Almeida e Val, Fernando F., de Lacerda, Marcus V. G., de Melo, Gisely C., Derde, Lennie, Dubee, Vincent, Elfakir, Anissa, Gordon, Anthony C., Hernandez-Cardenas, Carmen M., Hills, Thomas, Hoepelman, Andy I. M., Huang, Yi-Wen, Igau, Bruno, Jin, Ronghua, Jurado-Camacho, Felipe, Khan, Khalid S., Kremsner, Peter G., Kreuels, Benno, Kuo, Cheng-Yu, Le, Thuy, Lin, Yi-Chun, Lin, Wu-Pu, Lin, Tse-Hung, Lyngbakken, Magnus Nakrem, McArthur, Colin, McVerry, Bryan J., Meza-Meneses, Patricia, Monteiro, Wuelton M., Morpeth, Susan C., Mourad, Ahmad, Mulligan, Mark J., Murthy, Srinivas, Naggie, Susanna, Narayanasamy, Shanti, Nichol, Alistair, Novack, Lewis A., O’Brien, Sean M., Okeke, Nwora Lance, Perez, Léna, Perez-Padilla, Rogelio, Perrin, Laurent, Remigio-Luna, Arantxa, Rivera-Martinez, Norma E., Rockhold, Frank W., Rodriguez-Llamazares, Sebastian, Rolfe, Robert, Rosa, Rossana, Røsjø, Helge, Sampaio, Vanderson S., Seto, Todd B., Shahzad, Muhammad, Soliman, Shaimaa, Stout, Jason E., Thirion-Romero, Ireri, Troxel, Andrea B., Tseng, Ting-Yu, Turner, Nicholas A., Ulrich, Robert J., Walsh, Stephen R., Webb, Steve A., Weehuizen, Jesper M., Velinova, Maria, Wong, Hon-Lai, Wrenn, Rebekah, Zampieri, Fernando G., Zhong, Wu, Moher, David, Goodman, Steven N., Ioannidis, John P. A., and Hemkens, Lars G.

Published
2021
Full Text
View/download PDF

28. Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial

Author

Rouphael, Nadine G., Lai, Lilin, Tandon, Sonia, McCullough, Michele Paine, Kong, Yunchuan, Kabbani, Sarah, Natrajan, Muktha S., Xu, Yongxian, Zhu, Yerun, Wang, Dongli, O’Shea, Jesse, Sherman, Amy, Yu, Tianwei, Henry, Sebastien, McAllister, Devin, Stadlbauer, Daniel, Khurana, Surender, Golding, Hana, Krammer, Florian, Mulligan, Mark J., and Prausnitz, Mark R.

Published
2021
Full Text
View/download PDF

29. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

Author

Axfors, Cathrine, Schmitt, Andreas M., Janiaud, Perrine, van’t Hooft, Janneke, Abd-Elsalam, Sherief, Abdo, Ehab F., Abella, Benjamin S., Akram, Javed, Amaravadi, Ravi K., Angus, Derek C., Arabi, Yaseen M., Azhar, Shehnoor, Baden, Lindsey R., Baker, Arthur W., Belkhir, Leila, Benfield, Thomas, Berrevoets, Marvin A. H., Chen, Cheng-Pin, Chen, Tsung-Chia, Cheng, Shu-Hsing, Cheng, Chien-Yu, Chung, Wei-Sheng, Cohen, Yehuda Z., Cowan, Lisa N., Dalgard, Olav, de Almeida e Val, Fernando F., de Lacerda, Marcus V. G., de Melo, Gisely C., Derde, Lennie, Dubee, Vincent, Elfakir, Anissa, Gordon, Anthony C., Hernandez-Cardenas, Carmen M., Hills, Thomas, Hoepelman, Andy I. M., Huang, Yi-Wen, Igau, Bruno, Jin, Ronghua, Jurado-Camacho, Felipe, Khan, Khalid S., Kremsner, Peter G., Kreuels, Benno, Kuo, Cheng-Yu, Le, Thuy, Lin, Yi-Chun, Lin, Wu-Pu, Lin, Tse-Hung, Lyngbakken, Magnus Nakrem, McArthur, Colin, McVerry, Bryan J., Meza-Meneses, Patricia, Monteiro, Wuelton M., Morpeth, Susan C., Mourad, Ahmad, Mulligan, Mark J., Murthy, Srinivas, Naggie, Susanna, Narayanasamy, Shanti, Nichol, Alistair, Novack, Lewis A., O’Brien, Sean M., Okeke, Nwora Lance, Perez, Léna, Perez-Padilla, Rogelio, Perrin, Laurent, Remigio-Luna, Arantxa, Rivera-Martinez, Norma E., Rockhold, Frank W., Rodriguez-Llamazares, Sebastian, Rolfe, Robert, Rosa, Rossana, Røsjø, Helge, Sampaio, Vanderson S., Seto, Todd B., Shahzad, Muhammad, Soliman, Shaimaa, Stout, Jason E., Thirion-Romero, Ireri, Troxel, Andrea B., Tseng, Ting-Yu, Turner, Nicholas A., Ulrich, Robert J., Walsh, Stephen R., Webb, Steve A., Weehuizen, Jesper M., Velinova, Maria, Wong, Hon-Lai, Wrenn, Rebekah, Zampieri, Fernando G., Zhong, Wu, Moher, David, Goodman, Steven N., Ioannidis, John P. A., and Hemkens, Lars G.

Published
2021
Full Text
View/download PDF

30. SARS-CoV-2 inflammation durably imprints memory CD4 T cells.

Author

Gray-Gaillard, Sophie L., Solis, Sabrina M., Chen, Han M., Monteiro, Clarice, Ciabattoni, Grace, Samanovic, Marie I., Cornelius, Amber R., Williams, Tijaana, Geesey, Emilie, Rodriguez, Miguel, Ortigoza, Mila Brum, Ivanova, Ellie N., Koralov, Sergei B., Mulligan, Mark J., and Herati, Ramin Sedaghat

Subjects
IMMUNOLOGIC memory, SARS-CoV-2, BREAKTHROUGH infections, INFLAMMATION, T cells
Abstract

Memory CD4 T cells are critical to human immunity, yet it is unclear whether viral inflammation during memory formation has long-term consequences. Here, we compared transcriptional and epigenetic landscapes of Spike (S)–specific memory CD4 T cells in 24 individuals whose first exposure to S was via SARS-CoV-2 infection or mRNA vaccination. Nearly 2 years after memory formation, S-specific CD4 T cells established by infection remained enriched for transcripts related to cytotoxicity and for interferon-stimulated genes, likely because of a chromatin accessibility landscape altered by inflammation. Moreover, S-specific CD4 T cells primed by infection had reduced proliferative capacity in vitro relative to vaccine-primed cells. Furthermore, the transcriptional state of S-specific memory CD4 T cells was minimally altered by booster immunization and/or breakthrough infection. Thus, infection-associated inflammation durably imprints CD4 T cell memory, which affects the function of these cells and may have consequences for long-term immunity. Editor's summary: It is unclear whether the memory CD4 T cells generated via mRNA vaccination and via SARS-CoV-2 infection are comparable in terms of frequency and function. Gray-Gaillard et al. performed single-cell analysis of spike protein (S)–specific memory CD4 T cells taken from a longitudinal sample of individuals variously vaccinated against SARS-CoV-2 or naturally infected with the virus. Infection-primed S-specific memory CD4 T cells exhibited a durable transcriptional and epigenetic signature of inflammation, a cytotoxic profile, and a proliferative disadvantage compared with vaccine-primed memory CD4 T cells. Breakthrough infections did not generally alter the transcriptional profile of vaccine-primed memory T cells, although re-exposure to antigen accompanied by high levels of inflammation could alter the transcriptional profiles of these cells in a clonotype-specific manner. —Seth Thomas Scanlon [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Innate, T-, and B-Cell Responses in Acute Human Zika Patients

Author

Emory Zika Patient Study Team, Lai, Lilin, Rouphael, Nadine, Xu, Yongxian, Natrajan, Muktha S., Beck, Allison, Hart, Mari, Feldhammer, Matthew, Feldpausch, Amanda, Hill, Charles, Wu, Henry, Fairley, Jessica K., Lankford-Turner, Pamela, Kasher, Nicole, Rago, Patrick, Hu, Yi-Juan, Edupuganti, Srilatha, Patel, Shital M., Murray, Kristy O., and Mulligan, Mark J.

Published
2018

34. Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial

Author

Janes, Holly E., Cohen, Kristen W., Frahm, Nicole, De Rosa, Stephen C., Sanchez, Brittany, Hural, John, Magaret, Craig A., Karuna, Shelly, Bentley, Carter, Gottardo, Raphael, Finak, Greg, Grove, Douglas, Shen, Mingchao, Graham, Barney S., Koup, Richard A., Mulligan, Mark J., Koblin, Beryl, Buchbinder, Susan P., Keefer, Michael C., Adams, Elizabeth, Anude, Chuka, Corey, Lawrence, Sobieszczyk, Magdalena, Hammer, Scott M., Gilbert, Peter B., and McElrath, M. Juliana

Published
2017

35. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial

Author

Beck, Allison, Edupuganti, Srilatha, Heeke, Sheila, Kelley, Colleen, Nesheim, Wendy, Rouphael, Nadine G, Paine, Michele, Mosley, Regina, Henry, Sebastien, McAllister, Devin V, Kalluri, Haripriya, Pewin, Winston, Frew, Paula M, Yu, Tianwei, Thornburg, Natalie J, Kabbani, Sarah, Lai, Lilin, Vassilieva, Elena V, Skountzou, Ioanna, Compans, Richard W, Mulligan, Mark J, and Prausnitz, Mark R

Published
2017
Full Text
View/download PDF

36. Metabolic Phenotypes of Response to Vaccination in Humans

Author

Li, Shuzhao, Sullivan, Nicole L., Rouphael, Nadine, Yu, Tianwei, Banton, Sophia, Maddur, Mohan S., McCausland, Megan, Chiu, Christopher, Canniff, Jennifer, Dubey, Sheri, Liu, Ken, Tran, ViLinh, Hagan, Thomas, Duraisingham, Sai, Wieland, Andreas, Mehta, Aneesh K., Whitaker, Jennifer A., Subramaniam, Shankar, Jones, Dean P., Sette, Alessandro, Vora, Kalpit, Weinberg, Adriana, Mulligan, Mark J., Nakaya, Helder I., Levin, Myron, Ahmed, Rafi, and Pulendran, Bali

Published
2017
Full Text
View/download PDF

37. Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants.

Author

Cardemil, Cristina V., Yi Cao, Posavad, Christine M., Badell, Martina L., Bunge, Katherine, Mulligan, Mark J., Parameswaran, Lalitha, Olson-Chen, Courtney, Novak, Richard M., Brady, Rebecca C., DeFranco, Emily, Gerber, Jeffrey S., Pasetti, Marcela, Shriver, Mallory, Coler, Rhea, Berube, Bryan, Suthar, Mehul S., Moreno, Alberto, Fei Gao, and Richardson, Barbra A.

Published
2024
Full Text
View/download PDF

38. Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirus

Author

Wong, Karen K., Davey, Richard T., Hewlett, Angela L., Kraft, Colleen S., Mehta, Aneesh K., Mulligan, Mark J., Beck, Allison, Dorman, William, Kratochvil, Christopher J., Lai, Lilin, Palmore, Tara N., Rogers, Susan, Smith, Philip W., Suffredini, Anthony F., Wolcott, Mark, Ströher, Ute, and Uyeki, Timothy M.

Published
2016

40. Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083

Author

HVTN 083 Study Group, NIAID HVTN, Walsh, Stephen R., Moodie, Zoe, Fiore-Gartland, Andrew J., Morgan, Cecilia, Wilck, Marissa B., Hammer, Scott M., Buchbinder, Susan P., Kalams, Spyros A., Goepfert, Paul A., Mulligan, Mark J., Keefer, Michael C., Baden, Lindsey R., Swann, Edith M., Grant, Shannon, Ahmed, Hasan, Li, Fusheng, Hertz, Tomer, Self, Steven G., Friedrich, David, Frahm, Nicole, Liao, Hua-Xin, Montefiori, David C., Tomaras, Georgia D., McElrath, M. Juliana, Hural, John, Graham, Barney S., and Jin, Xia

Published
2016

41. Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures

Author

Nakaya, Helder I., Hagan, Thomas, Duraisingham, Sai S., Lee, Eva K., Kwissa, Marcin, Rouphael, Nadine, Frasca, Daniela, Gersten, Merril, Mehta, Aneesh K., Gaujoux, Renaud, Li, Gui-Mei, Gupta, Shakti, Ahmed, Rafi, Mulligan, Mark J., Shen-Orr, Shai, Blomberg, Bonnie B., Subramaniam, Shankar, and Pulendran, Bali

Published
2015
Full Text
View/download PDF

42. Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Author

Mulligan, Mark J., Lyke, Kirsten E., Kitchin, Nicholas, Absalon, Judith, Gurtman, Alejandra, Lockhart, Stephen, Neuzil, Kathleen, Raabe, Vanessa, Bailey, Ruth, Swanson, Kena A., Li, Ping, Koury, Kenneth, Kalina, Warren, Cooper, David, Fontes-Garfias, Camila, Shi, Pei-Yong, Türeci, Özlem, Tompkins, Kristin R., Walsh, Edward E., Frenck, Robert, Falsey, Ann R., Dormitzer, Philip R., Gruber, William C., Şahin, Uğur, and Jansen, Kathrin U.

Published
2021
Full Text
View/download PDF

46. The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States

Author

Kraft, Colleen S., Hewlett, Angela L., Koepsell, Scott, Winkler, Anne M., Kratochvil, Christopher J., Larson, LuAnn, Varkey, Jay B., Mehta, Aneesh K., Lyon, G. Marshall, Friedman-Moraco, Rachel J., Marconi, Vincent C., Hill, Charles E., Sullivan, James N., Johnson, Daniel W., Lisco, Steven J., Mulligan, Mark J., Uyeki, Timothy M., McElroy, Anita K., Sealy, Tara, Campbell, Shelley, Spiropoulou, Christina, Ströher, Ute, Crozier, Ian, Sacra, Richard, Connor, Michael J., Sueblinvong, Viranuj, Franch, Harold A., Smith, Philip W., and Ribner, Bruce S.

Published
2015
Full Text
View/download PDF

48. Biphasic Zika Illness With Rash and Joint Pain

Author

Edupuganti, Srilatha, Natrajan, Muktha S, Rouphael, Nadine, Lai, Lilin, Xu, Yongxian, Feldhammer, Matthew, Hill, Charles, Patel, Shital M, Johnson, Sara Jo, Bower, Mary, Gorchakov, Rodion, Berry, Rebecca, Murray, Kristy O, and Mulligan, Mark J

Published
2017
Full Text
View/download PDF

50. Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles

Author

Goepfert, Paul A., Elizaga, Marnie L., Seaton, Kelly, Tomaras, Georgia D., Montefiori, David C., Sato, Alicia, Hural, John, DeRosa, Stephen C., Kalams, Spyros A., McElrath, M. Juliana, Keefer, Michael C., Baden, Lindsey R., Lama, Javier R., Sanchez, Jorge, Mulligan, Mark J., Buchbinder, Susan P., Hammer, Scott M., Koblin, Beryl A., Pensiero, Michael, Butler, Chris, Moss, Bernard, and Robinson, Harriet L.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results